Mag Cal Plus
En vente sur le marché américain (selon le DSLD)
Genestra Brands, food supplement from the US market
Mag Cal Plus (Genestra Brands), a food supplement au code-barres 883196103300, is described by its US market label. If sold in France, it would be subject to 4 points of French or European regulation, detailed below. Doses of niacine are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine D: up to 7.5 µg a day according to the label (at most 3 servings a day), above the maximum dose of 5 µg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- Dose déclarée au-delà d'une limite
Vitamine B6: up to 7.5 mg a day according to the label (at most 3 servings a day), above the maximum dose of 2 mg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- Dose déclarée au-delà d'une limite
Magnésium: up to 450 mg a day according to the label (at most 3 servings a day), above the maximum dose of 300 mg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- À vérifier
Magnésium: up to 450 mg a day according to the label, above the limite de sécurité from EFSAEuropean Food Safety Authority. for adults (250 mg a day). Pour ce nutriment, le repère de l'EFSA ne porte que sur les apports ajoutés (compléments, aliments enrichis), pas sur ce qu'apporte l'alimentation courante.
Source: EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), limite supérieure de sécurité (UL).
- Conditions légales
Valeriana officinalis L.: L'absence de valépotriates doit être prouvée par des rapports d'analyse. L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Genestra Brands
- Barcode
- 883196103300
- Form
- Tablet
- One serving
- 1 tablet
- Servings
- up to 3 servings per day
- Other ingredients (in English, as written)
- Cellulose, Hyprolose, Croscarmellose Sodium, Hypromellose, Glycerin, Silica
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Vitamin C | Vitamin | 9 mg |
| Vitamin D3 | Vitamin | 2.5 µg |
| Niacin | Vitamin | 6.25 mg |
| Vitamin B6 | Vitamin | 2.5 mg |
| Calcium | Mineral | 100 mg |
| Magnesium | Mineral | 150 mg |
| Valerian root extract (Valeriana officinalis) | Plant | 25 mg |
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Mag Cal Plus
Entered into DSLD on 28 May 2019. Retirée du marché américain le 21 July 2021 (selon le DSLD).- Active ingredient added : Valerian (30 mg)
- Active ingredient removed : Valerian root extract (25 mg)
- Active ingredient removed : Vitamin C (9 mg)
- Same quantity, different name: Vitamin D in this version; Vitamin D3 on the displayed label (2.5 mcg)
Official label: Mag Cal Plus
Entered into DSLD on 25 January 2016. Retirée du marché américain le 8 November 2024 (selon le DSLD).- Active ingredient added : Valerian (30 mg)
- Active ingredient added : Vitamin D (100 IU)
- Active ingredient removed : Valerian root extract (25 mg)
- Active ingredient removed : Vitamin C (9 mg)
- Active ingredient removed : Vitamin D3 (2.5 mcg)
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Vitamin D3
Read the warning, when it applies and the studies cited
VITAMIN D (>1,000 - 2,500 IU)
Route of administration: Oral
Cautions and warnings
Condition of application: All products except products containing zinc sourced from picolinate requiring a contraindication.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney disorders (NIH 2024; BfR 2020).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other supplements or products containing vitamin D or vitamin D analogues.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any medications including antacids, anticonvulsants, digoxin, cholestyramine, colestipol, mineral oil, steroids, statins or thiazide diuretics (NNHPD 2021; BfR 2020).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to determine if you would benefit from additional vitamin D as 15-20 mcg (600-800 IU) of vitamin D per day is an adequate quantity for most individuals.
Applies to products containing vitamin K2.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (NNHPD 2026).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Applies to products providing 25-34 mg of zinc per day for adults 18 years or 31-50 mg of zinc per day for adults 19 years and older.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are unsure whether you are taking enough copper as zinc supplementation can cause a copper deficiency (NNHPD 2026).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Condition of application: All products.
Do not use if you have hypercalcemia and/or hypercalciuria (NIH 2024; BfR 2020).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Applies to products containing zinc sourced from picolinate.
Do not use if you are pregnant or breastfeeding (NNHPD 2026).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Condition of application: All products.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if the following early symptoms of hypercalcemia occur: weakness, fatigue, drowsiness, headache, lack of appetite, dry mouth, metallic taste, nausea, vomiting, vertigo, ringing in the ears, lack of coordination and muscle weakness or if you develop any other symptom (NIH 2024; BfR 2020).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Applies to products providing more than 350 mg of magnesium per day.
When using this product you may experience diarrhea (NNHPD 2026).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Valerian root extract
Read the warning, when it applies and the studies cited
Valerian - VALERIANA OFFICINALIS
Route of administration: Oral
Cautions and warnings
Condition of application: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Mills et al. 2006; Blumenthal et al. 2003; Barnes et al. 2002).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010; Gennaro et al. 2000).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2016; ESCOP 2003; Bradley 1992).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (EMA 2016; Berardi et al. 2002; Dipiro et al. 2002).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Genestra Brands
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.